JACKSONVILLE, FL, May 04, 2026
Medical Microinstruments (MMI) has successfully treated the first patient in its FDA-approved REMIND clinical study, marking a major milestone in the use of robotic-assisted microsurgery for Alzheimer’s disease. The procedure, performed using the Symani® Surgical System, represents the first-ever clinical application of robotic lymphatic microsurgery in a neurodegenerative disorder. This early feasibility study, conducted under an Investigational Device Exemption (IDE), is designed to evaluate the safety and feasibility of this novel approach in patients with moderate Alzheimer’s disease, with further clinical insights expected as the study progresses.
First-in-Human Study Targets Neurodegenerative Disease
The REMIND trial (Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease) is a multi-center clinical study that plans to enroll 15 patients, each undergoing a robotic-assisted microsurgical procedure targeting the deep cervical lymph nodes (dCLNs).
The goal is to assess whether restoring lymphatic drainage pathways can enhance the clearance of neurotoxic waste, a key factor believed to contribute to Alzheimer’s progression. Patients will be monitored over a 12-month follow-up period, with primary endpoints focused on device-related safety outcomes within 30 days, alongside secondary endpoints including biomarker changes, imaging data, and cognitive assessments.
Symani System Enables Precision Microsurgery
Advertisement
At the center of this clinical innovation is the Symani® Surgical System, a robotic platform designed for supermicrosurgical precision, capable of operating on extremely small anatomical structures. The system integrates motion scaling and tremor reduction technologies, allowing surgeons to perform delicate procedures that are otherwise beyond human capability.
In this study, Symani is used to explore lymphovenous bypass techniques in the neck region, representing a completely new application of robotic surgery in neurology and neurovascular intervention. This convergence of robotics, lymphatic biology, and neuroscience reflects a growing trend toward interdisciplinary clinical innovation.
Clinical Collaboration and Future Impact
The inaugural procedure was performed by a multidisciplinary team at Baptist Health in Jacksonville, involving experts in microsurgery, neurology, and neuroradiology, highlighting the complexity of this emerging treatment approach. The study builds on a decade of preclinical and translational research exploring the role of the glymphatic system in brain health.
While the safety and effectiveness of this approach have not yet been established, the data generated from REMIND will be critical in determining whether this technique can progress to larger pivotal trials. If successful, this approach could redefine how neurodegenerative diseases like Alzheimer’s are treated, shifting from purely pharmaceutical interventions to surgical and device-based solutions.
MMI’s REMIND study represents a high-risk, high-reward clinical innovation, where success depends on translating complex biological hypotheses into measurable patient outcomes. While early-stage and limited in scale, this trial could open entirely new therapeutic pathways in Alzheimer’s treatment, an area with massive unmet clinical need. The real challenge will be proving not just technical feasibility, but also meaningful clinical benefit, which remains the ultimate benchmark for adoption in modern medicine.
Source: MMI press release
